Periampulläre Tumoren: Therapie und Prognose

Torsten Herzog; Waldemar Uhl

doi:10.1055/a-1382-5917

Onkologie up2date, Table of Contents

Onkologie up2date 2021; 3(02): 127-141
DOI: 10.1055/a-1382-5917

Tumoren des Gastrointestinaltraktes

Periampulläre Tumoren: Therapie und Prognose

Torsten Herzog

,

Waldemar Uhl

Abstract

All articles of this category

Periampulläre Tumoren umfassen gut- und bösartige Neubildungen des Pankreaskopfes, des distalen Gallengangs, des Duodenums und der Ampulla Vateri. Während der 1. Teil des Artikels die Klassifikation dieser Tumoren, die Anatomie, die Symptomatik und das diagnostische Vorgehen beschreibt [1], widmet sich dieser 2. Teil der Therapie sowie der Prognose.

Schlüsselwörter

Tumorchirurgie - distales Gallengangkarzinom - Karzinom der Ampulla Vateri - Duodenalkarzinom - Duodenaladenom

Full Text

References

Literatur
1 Herzog T, Uhl W. Periampulläre Tumoren – Teil 1: Epidemiologie, Einteilung und Diagnostik. Allg Viszeralchir up2date 2019; 14: 187-200
2 Ochiai Y, Kato M, Kiguchi Y. et al. Current status and challenges of endoscopic treatments for duodenal tumors. Digestion 2019; 99: 21-26
3 Hara Y, Goda K, Dobashi A. et al. Short-and long-term outcomes of endoscopically treated superficial non-ampullary duodenal epithelial tumors. World J Gastroenterol 2019; 25: 707-718
4 Yamamoto K, Itoi T, Sofuni A. et al. Expanding the indication of endoscopic papillectomy for T1a ampullary carcinoma. Digest Endosc 2019; 31: 188-196
5 Attila T, Parlak E, Alper E. et al. Endoscopic papillectomy of benign ampullary lesions: Outcomes from a multicenter study. Turk J Gastroenterol 2018; 29: 325-334
6 Sakai A, Tsujimae M, Masuda A. et al. Clinical outcomes of ampullary neoplasms in resected margin positive or uncertain cases after endoscopic papillectomy. World J Gastroenterol 2019; 25: 1387-1397
7 Herzog T. Prävention und Therapie biliärer Komplikationen bei pankreaschirurgischen Eingriffen [Kumulative Habilitationsschrift]. Bochum: Ruhr Universität Bochum; 2016
8 Wierick A, Distler M, Weitz J. et al. Tumoren der Papille und des Duodenums. Allg Viszeralchir up2date 2016; 10: 183-198
9 Parc Y, Mabrut JY, Shields C. et al. Surgical management of the duodenal manifestations of familial adenomatous polyposis. Br J Surg 2011; 98: 480-484
10 Sarmiento JM, Thompson GB, Nagorney DM. et al. Pancreas-sparing Duodenectomy for Duodenal Polyposis. Arch Surg 2002; 137: 557-563
11 Belyaev O, Uhl W. Pankreaskarzinom – Chirurgie im Wandel der multimodalen Therapiemöglichkeiten. Allg Viszeralchir up2date 2019; 13: 511-530
12 Strijker M, Belkouz A, van der Geest LG. et al. Treatment and survival of resected and unresected distal cholangiocarcinoma: a nationwide study. Acta Oncol 2019; 58: 1048-1055
13 Al-Jumayli M, Batool A, Middiniti A. et al. Clinical outcome of ampullary carcinoma: single cancer center experience. J Oncol 2019; 2019: 3293509
14 Bowitz Lothe IM, Kleive D, Pomianowska E. et al. Clinical relevance of pancreatobiliary and intestinal subtypes of ampullary and duodenal adenocarcinoma: Pattern of recurrence, chemotherapy, and survival after pancreatoduodenectomy. Pancreatology 2019; 19: 316-324
15 Zimmermann C, Wolk S, Aust DE. et al. The pathohistological subtype strongly predicts survival in patients with ampullary carcinoma. Sci Rep 2019; 9: 12676
16 Meijer LL, Alberga AJ, de Bakker JK. et al. Outcomes and treatment options for duodenal adenocarcinoma: a systematic review and meta-analysis. Ann Surg Oncol 2018; 25: 2681-2692
17 RKI. Krebs in Deutschland 2015/2016. Im Internet (Stand: 23.12.2019): https://www.rki.de/DE/Content/Gesundheitsmonitoring/Krebsregisterdaten/krebs_node.html
18 Ecker BL, Vollmer jr. CM, Behrman SW. et al. Role of adjuvant multimodality therapy after curative-intent resection of ampullary carcinoma. JAMA Surg 2019;
19 Tsen A, Barbara M, Rosenkranz L. Dilemma of elevated CA 19-9 in biliary pathology. Pancreatology 2018; 18: 862-867
20 Trape J, Filella X, Alsina-Donadeu M. et al. Increased plasma concentrations of tumour markers in the absence of neoplasia. Clin Chem Lab Med 2011; 49: 1605-1620
21 Belyaev O, Munding J, Tannapfel A. et al. False-positive PET/CT after cyanoacrylate sealing of a pancreaticojejunostomy. J Gastrointest Surg 2015; 19: 984-985
22 Regalla DKR, Jacob R, Manne A. et al. Therapeutic options for ampullary carcinomas. A review. Oncol Rev 2019; 13: 440
23 Nappo G, Gentile D, Galvanin J. et al. Trans-duodenal ampullectomy for ampullary neoplasms: early and long-term outcomes in 36 consecutive patients. Surg Endosc 2019;
24 Weitz J, Rahbari N, Koch M. et al. The “artery first” approach for resection of pancreatic head cancer. J Am Coll Surg 2010; 210: e1-e4
25 Tol JA, Gouma DJ, Bassi C. et al. Definition of a standard lymphadenectomy in surgery for pancreatic ductal adenocarcinoma: a consensus statement by the International Study Group on Pancreatic Surgery (ISGPS). Surgery 2014; 156: 591-600
26 Uhl W, Sülberg D. Pyloruserhaltende Duodenohemipankreatektomie nach Traverso-Longmire mit T-Drainage (pp-Whipple). Im Internet (Stand: 21.02.2020): https://www.webop.de/Allgemein-und-Viszeralchirurgie/Pankreas-und-Milz/Pyloruserhaltende-Duodenohemipankreatektomie-nach-Traverso-Longmire-mit-T-Drainage-pp-Whipple
27 Krautz C, Nimptsch U, Weber GF. et al. Effect of hospital volume on in-hospital morbidity and mortality following pancreatic surgery in Germany. Ann Surg 2018; 267: 411-417
28 Limongelli P, Khorsandi SE, Pai M. et al. Management of delayed postoperative hemorrhage after pancreaticoduodenectomy: a meta-analysis. Arch Surg 2008; 143: 1001-1007 discussion 1007
29 Popivanov GI, Mutafchiyski VM, Cirocchi R. et al. Endoluminal negative pressure therapy in colorectal anastomotic leaks. Im Internet: Colorect Dis 2019;
30 Bassi C, Dervenis C, Butturini G. et al. Postoperative pancreatic fistula: an international study group (ISGPF) definition. Surgery 2005; 138: 8-13
31 Koch M, Garden OJ, Padbury R. et al. Bile leakage after hepatobiliary and pancreatic surgery: a definition and grading of severity by the International Study Group of Liver Surgery. Surgery 2011; 149: 680-688
32 Khalsa BS, Imagawa DK, Chen JI. et al. Evolution in the treatment of delayed postpancreatectomy hemorrhage: surgery to interventional radiology. Pancreas 2015; 44: 953-958
33 Ecker BL, McMillan MT, Datta J. et al. Adjuvant chemotherapy versus chemoradiotherapy in the management of patients with surgically resected duodenal adenocarcinoma: A propensity score-matched analysis of a nationwide clinical oncology database. Cancer 2017; 123: 967-976
34 Primrose JN, Fox RP, Palmer DH. et al. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. Lancet Oncol 2019; 20: 663-673
35 Onkologie DGfHuM. Karzinome der Gallengänge und Gallenblase-Empfehlungen der Fachgesellschaft zur Diagnostik und Therapie hämatologischer und onkologischer Erkrankungen. Im Internet (Stand: 17.09.2019): https://www.onkopedia.com/de/onkopedia/guidelines/maligne-biliaere-tumoren/@@guideline/html/index.html
36 Ye X, Zhang G, Chen H. et al. Meta-analysis of postoperative adjuvant therapy for small bowel adenocarcinoma. PLoS One 2018; 13: e0200204
37 Cameron JL, He J. Two thousand consecutive pancreaticoduodenectomies. J Am Coll Surg 2015; 220: 530-536
38 Petrova E, Ruckert F, Zach S. et al. Survival outcome and prognostic factors after pancreatoduodenectomy for distal bile duct carcinoma: a retrospective multicenter study. Langenbecks Arch Surg 2017; 402: 831-840
39 Zhou Y, Liu S, Wu L. et al. Survival after surgical resection of distal cholangiocarcinoma: A systematic review and meta-analysis of prognostic factors. Asian J Surg 2017; 40: 129-138
40 Courtin-Tanguy L, Turrini O, Bergeat D. et al. Multicentre study of the impact of factors that may affect long-term survival following pancreaticoduodenectomy for distal cholangiocarcinoma. HPB (Oxford) 2018; 20: 405-410
41 Li HB, Zhao FQ, Zhou J. Prognostic nomogram for disease-specific survival in patients with non-metastatic ampullary carcinoma after surgery. Ann Surg Oncol 2019; 26: 1079-1085
42 Marabelle A, Le DT, Ascierto PA. et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol 2020; 38: 1-10